Akebia Therapeutics, Inc. (FRA:AX9)

Market Cap	314.94M -23.4%
Revenue (ttm)	191.83M +32.5%
Net Income	-13.56M
EPS	-0.06
Shares Out	n/a
PE Ratio	n/a
Forward PE	12.91
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	150
Open	1.184
Previous Close	1.180
Day's Range	1.184 - 1.184
52-Week Range	1.116 - 3.538
Beta	n/a
RSI	42.95
Earnings Date	Mar 12, 2026

About Akebia Therapeutics

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the t...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 181
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: AX9

Financial Performance

In 2024, Akebia Therapeutics's revenue was $160.18 million, a decrease of -17.70% compared to the previous year's $194.62 million. Losses were -$69.41 million, 33.7% more than in 2023.

Financial numbers in USD